Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.

Patients who initiate nintedanib promptly after IPF diagnosis may have reduced hospitalization risk and medical costs compared with those who start treatment later. Additional studies are warranted to improve understanding of the impact of prompt antifibrotic therapy on patient outcomes.